This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Real validated GFPT1 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-GFPT1 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
| Expected band | ~78.8 kDa | |
| Observed band | 79 kDa | |
| Gel | 10–12% | |
| Negative control | siRNA / KO lysate |
| PTM | Phosphorylated | |
| Caveat | Alternative splicing isoforms | |
| Regulation | Glycolysis | |
| Isoform | 2 isoform(s) |
Literature-validated Western blot parameters for GFPT1 — gel percentage, transfer, blocking, antibody incubation and detection, extracted from published methods.
| Sample / lysate | human HepG2 , Lane 2: human Hela , Lane 3: human 293T , Lane 4: human MCF-7 , Lane 5: human Caco-2 , Lane 6: human HEL . After electrophoresis, proteins were transferred to a nitrocellulose membrane at 150 mA for 50-90 minutes. Blocked the membrane with 5% non-fat milk/TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-GFPT1 antigen affinity purified polyclonal antibody (Catalog # A04341-1) at 0.5 μg/mL overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:5000 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1002) with Tanon 5200 system. A specific band was detected for GFPT1 at approximately 79 kDa. The expected band size for GFPT1 is at 79 kDa |
| Gel % | 10–12% |
| Load | 30 ug |
| Transfer | nitrocellulose membrane, 150 mA, 50–90 min |
| Membrane | nitrocellulose |
| Blocking | 5% non-fat milk / TBS, 1.5 h RT |
| Primary antibody | 0.5 µg/mL |
| Primary incubation | overnight at 4 °C |
| Secondary antibody | goat anti-rabbit IgG-HRP, 1:5000 |
| Wash | TBS-0.1% Tween, 3 × 5 min |
| Detection | ECL |
| Exposure / imaging | Tanon 5200 |
| Observed band | 79 kDa |
GFPT1 has a 78.8 kDa predicted mass and runs as a single ~79 kDa band, with higher bands appearing only if homodimer or homotetramer persists under incomplete reduction.
| Single sharp band near 79 kDa | matches the unmodified GFPT1 monomer, which carries no glycosylation or cleavage to shift its size |
| Band at roughly double the monomer size under non-reducing or incompletely reduced conditions | reflects the homodimer GFPT1 forms as an asymmetric dimer |
| Faint higher-order band at roughly four times the monomer size under native conditions | reflects homotetramer assembly reported for GFPT1 by similarity |
| Two bands at slightly different apparent sizes | reflects co-detection of the two annotated GFPT1 splice isoforms |
| No smearing or diffuse upward shift across sample types | consistent with GFPT1 having no annotated glycosylation to add mass heterogeneity |
| Predicted molecular mass (78.8 kDa) | sets the baseline monomer size, consistent with the ~79 kDa band observed empirically |
| Homodimer formation (asymmetric dimer) | incomplete reduction or non-reducing conditions can leave a band at roughly double the monomer mass, while full reduction resolves it back to monomer |
| Homotetramer formation (by similarity) | under native, non-denaturing conditions can produce a higher-order band at roughly four times the monomer mass, not expected on standard reducing SDS-PAGE |
| Splice isoforms 1 and 2 | presence of the non-canonical isoform can add a second band of a qualitatively different apparent size alongside the canonical band |
| Situation | Likely cause | Next action |
|---|---|---|
| Band higher than expected | incomplete reduction or denaturation leaves residual GFPT1 homodimer or homotetramer intact | increase reducing agent concentration and boil samples longer to fully dissociate oligomers before loading |
| Multiple bands | co-migration of splice isoform 2 alongside the canonical isoform, or a mix of monomer and incompletely dissociated dimer | confirm full reduction of the sample and check whether the antibody epitope is shared across both annotated isoforms |
| Weak or no signal | low endogenous GFPT1 expression in the tissue or cell line, or epitope interference near a phosphorylated serine | load more total protein and select an antibody with an epitope away from the annotated phosphoserine sites |
| Band lower than expected | proteolytic degradation during lysis generates a truncated GFPT1 fragment | add protease inhibitors to the lysis buffer and keep samples cold throughout preparation |
| Fragments below expected size | sample degradation from prolonged storage or repeated freeze-thaw cycles | use freshly prepared lysate and avoid multiple freeze-thaw cycles before running the gel |
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
| Tissue | Cell type | Level | Evidence | Source |
|---|
| Tissue | Cell type | Level | Evidence | Source |
|---|
Deeper troubleshooting and optimisation questions for GFPT1, answered from its protein features.
BosterBio's GFPT1 antibodies are among the best-performing WB antibodies on the market — well cited, thoroughly validated, and orthogonally cross-validated against negative tissues and complementary methods.
Our recommended anti-GFPT1 Western blot antibody is a best-performing, well-cited reagent, rigorously validated through extensive testing and orthogonally cross-validated against negative tissue controls and complementary methods, ensuring specific, reproducible detection for confident results.
Which to pick: Only one GFPT1 antibody is catalogued, A04341-1, so it's the clear choice here. It includes an authentic Western blot validation image confirming specific reactivity, giving you confidence in its performance before ordering.